VEGFC and lymphedema: These experiments revealed that the administration of VEGFC mRNA-LNPs effectively reduced paw thickness and clinical score in the experimental secondary lymphedema mouse model compared to the Poly(C) RNA-LNP control treatment (Fig. 9a).